Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
One Percent Rule Checklist For Safer Forex Trading Risk 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
PLYMOUTH, Minn., April 20, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced the Company plans to participate in the 42nd Annual Health Care Conference hosted by Deutsche Bank in Boston, MA.
Entellus Medical’s management is scheduled to present on Thursday, May 4, 2017 at 11:20am ET. Interested parties can access the live audio webcast at http://www.entellusmedical.com. An archived presentation will be available on the website.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of patients. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus Medical platform of products provides effective and easy-to-use solutions intended to help simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s core product lines, XprESS™ ENT Dilation System, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify treatment based in the operating room. Entellus Medical is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]
